Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Veracyte Inc VCYT
$45.43
โผ -6.41%
($-3.11)
Open
$49.00
Prev Close
$48.54
Day Range
$45.36 โ $49.00
52W Range
$29.46 โ $60.91
Market Cap
$3.65B
P/E (TTM)
34.09
Beta
2.01
EPS (TTM)
$1.40
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-30 |
| Shares Out. | 79,790,000 |
| Website | veracyte.com/ โ |
| Phone | 13026587581 |
| Employees | 755 |
| Revenue | $150.3M |
| Gross Profit | $108.5M |
| Net Income | $25.5M |
| Free Cash Flow | $166.0M |
| Total Assets | $1.49B |
| Total Liabilities | $98.0M |
| Equity | $1.39B |
About Veracyte Inc
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Veracyte Inc is a publicly traded company under the ticker symbol VCYT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
19 analysts (2026-09-01)
๐ฐ Latest News for VCYT
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

